Oncogenic Mutations in *GNAQ* Occur Early in Uveal Melanoma

Michael D. Onken,[1] *Lori A. Worley,*[1] *Meghan D. Long,*[1] *Shenghui Duan,*[2] *M. Laurin Council,*[2] *Anne M. Bowcock,*[2] *and J. William Harbour*[1]

PURPOSE. Early/initiating oncogenic mutations have been identified for many cancers, but such mutations remain unidentified in uveal melanoma (UM). An extensive search for such mutations was undertaken, focusing on the RAF/MEK/ERK pathway, which is often the target of initiating mutations in other types of cancer.

METHODS. DNA samples from primary UMs were analyzed for mutations in 24 potential oncogenes that affect the RAF/MEK/ERK pathway. For *GNAQ*, a stimulatory α_q G-protein subunit which was recently found to be mutated in UMs, resequencing was expanded to include 67 primary UMs and 22 peripheral blood samples. *GNAQ* status was analyzed for association with clinical, pathologic, chromosomal, immunohistochemical, and transcriptional features.

RESULTS. Activating mutations at codon 209 were identified in *GNAQ* in 33 (49%) of 67 primary UMs, including 2 (22%) of 9 iris melanomas and 31 (54%) of 58 posterior UMs. No mutations were found in the other 23 potential oncogenes. *GNAQ* mutations were not found in normal blood DNA samples. Consistent with *GNAQ* mutation being an early or initiating event, this mutation was not associated with any clinical, pathologic, or molecular features associated with late tumor progression.

CONCLUSIONS. *GNAQ* mutations occur in about half of UMs, representing the most common known oncogenic mutation in this cancer. The presence of this mutation in tumors at all stages of malignant progression suggests that it is an early event in UM. Mutations in this G-protein-coupled receptor provide new insights into UM pathogenesis and could lead to new therapeutic possibilities. (*Invest Ophthalmol Vis Sci.* 2008;49: 5230–5234) DOI:10.1167/iovs.08-2145

Uveal melanoma (UM) is the most common primary intraocular malignancy and the second most common form of melanoma. Several of the late genetic events in tumor progression and metastasis have been identified in UM, such as the loss of chromosome 3 and the switch from a class 1 (low metastatic risk) to a class 2 (high metastatic risk) gene expression profile.[1–3] In contrast, virtually nothing is known about the early, initiating events in uveal melanocytes leading to malignant transformation and development of a clinically detectable tumor. This deficiency stands in contrast to many other forms of cancer, including cutaneous melanoma, where early oncogenic mutations have been well characterized.

Perhaps the most common signaling pathway affected by early oncogenic mutations is the RAF/MEK/ERK pathway, where mutations in *BRAF*, *NRAS*, *HRAS*, and *KIT* lead to constitutive activation of the RAF/MEK/ERK pathway, which in turn stimulates the transcription of pro-proliferative genes such as *CCND1*, *JUN*, and *MYC*.[4,5] Curiously, mutations in these genes are extremely rare in UM.[6–8] Nevertheless, there is strong evidence that mutations affecting the RAF/MEK/ERK pathway are present in UM, since *MEK*, *ERK*, and *ELK* are constitutively activated in these tumors.[9,10] Further, the RAF/MEK/ERK pathway target *CCND1*, which encodes cyclin D1, is overexpressed in most UMs,[11,12] and leads to hyperphosphorylation and inactivation of the retinoblastoma tumor suppressor (Rb) in UM.[13,14] Since amplification of *CCND1* is rare in UM,[15] *CCND1* overexpression is most likely mediated transcriptionally by activation of the RAF/MEK/ERK pathway.

These lines of evidence implicating the RAF/MEK/ERK pathway as a likely location of early or initiating oncogenic mutations in UM prompted us to screen a large number of potential oncogenes in this pathway. This search included 24 genes and was guided by oncogenomic data from comparative genomic hybridization, transcription profiling, and in silico gene ontology analysis of public databases. Mutations in *GNAQ*, a stimulatory α_q subunit of heterotrimeric G-proteins that was recently found to be mutated in UM,[16] were found in half of the tumor samples, and the spectrum of *GNAQ* mutations suggested that this may be an early event in UM pathogenesis.

METHODS

Preparation of RNA and DNA

This study was approved by the Human Studies Committee at Washington University, and informed consent was obtained from each subject, in accordance with the Declaration of Helsinki. Tumor samples included 67 primary UMs (9 iris tumors and 58 posterior tumors). Normal DNA samples from peripheral blood were prepared from 22 patients with *GNAQ*-mutant tumors, as previously described.[17] Normal uveal melanocytes were available in two patients with *GNAQ*-mutant tumors (MM86 and MM101) who had undergone enucleation. To collect melanocytes, we cut the eye in half immediately after enucleation, and collected normal choroid from a location opposite the tumor, before collection of tumor tissue, so that none of the instruments touched the tumor. Melanocytes were then cultured from the choroid sample as previously described,[18] and DNA was obtained from these samples for *GNAQ* sequencing. Tumor tissue was then obtained, snap frozen, and prepared for RNA and DNA analysis, as previously described.[1,19] The technique and results of array-based comparative genomic hybridization (aCGH) were previously described.[19] The tech-

niques for generating transcription profile data in two gene arrays (Hu133A; Affymetrix, Santa Clara, CA, and Human Ref8 BeadChip; Illumina, San Diego, CA) have been described.[1,19,20]

Analysis of Array–CGH Profiles

Genome-wide CGH data were available on 28 primary UMs from a previously published study.[17] CGH profiles were analyzed using CGH-miner software (http://www-stat.stanford.edu/~wp57/CGH-Miner/ provided in the public domain by Stanford University Labs, Stanford, CA). Commercial statistical-analysis software (Excel; Microsoft, Redmond, WA) was used to identify small, discrete regions of DNA gain, defined as one or more contiguous probes with a $\log_2$ratio ≥ 3 SD of the mean for the entire chromosomal arm in at least 15% of tumor samples.

DNA Sequencing

Exon 5 of GNAQ was resequenced by routine methods after polymerase chain reaction amplification of exon 5 with primers: GNAQE5L: 5′-TTCCCTAAGTTTGTAAGTAGTGC and GNAQE5R:5′-AGAAGTAAGT-TCACTCCATTCC. This generated a product of 317 bp that included codon 209. Additional candidate oncogenes were resequenced to search for potential nucleic acid substitutions that could serve as activating mutations. Factors used to choose regions to be resequenced included: (1) the locations of reported cancer-related mutations in the Sanger Institute Catalog of Somatic Mutations (http://www.sanger. ac.uk/genetics/CGP/cosmic, provided in the public domain by the Wellcome Trust Sanger Institute Cancer Genome Project, Hinxton, UK), and (2) the locations of catalytic or regulatory domains in the Swiss-Prot Database (http://www.expasy.org/sprot/ provided in the public domain by the Swiss Institute of Bioinformatics, Geneva, Switzerland). For genes without known domains that would be likely targets for mutation, the entire coding region was resequenced. Primers were designed with Primer 3 software[21] to amplify all coding regions as well as exon–intron boundaries. Sequences were analyzed by computer (Sequencer 4.5 software; GeneCodes, Madison, WI). Nonsynonymous nucleotide changes were screened to rule out known single nucleotide polymorphisms (SNPs) by querying the alignment of the altered region with the reference DNA sequence in the University of California Santa Cruz (UCSC) genome browser (http://genome. ucsc.edu/). Primer sequences and other details of our sequencing strategy are available on request.

Analysis of Microarray Transcription Profiles

Twenty-nine of the tumors in this study (10 GNAQ wild-type and 19 GNAQ mutant) were analyzed for transcription profile using gene microarray (U133A GeneChip array [10 cases Affymetrix], the Bead-Chip array [14 cases; Illumina], or both [5 cases];).[1] The clinical, pathologic, and molecular information, and microarray platforms used for each tumor sample are indicated in Supplementary Table S1, http://www.iovs.org/cgi/content/full/49/12/5230/DC1. Affymetrix data were normalized by robust multichip average (RMA) using RMA-Express (written by Ben Bolstad and available in the public domain at rmaexpress.bmbolstad.com), and Illumina data were normalized by the rank invariant method using (BeadStudio software; Illumina). Principal component analysis (PCA) was performed to study unsupervised tumor clustering with respect to GNAQ status (Spotfire DecisionSite software; Tibco Software, Inc., Palo Alto, CA). Significance Analysis of Microarrays (SAM) was used to identify genes that were differentially expressed between tumors with and without GNAQ mutation (http:// www-stat.stanford.edu/~tibs/SAM; provided in the public domain by Stanford University Labs, Stanford, CA). Median centering and t-test statistic were used as analysis parameters, and the false discovery rate was set to zero. Class 1 and 2 tumors were analyzed separately. There were only four Affymetrix class 2 tumors, and so this subset was excluded from the analysis. The three subsets included: Affymetrix class 1 (six GNAQ wild-type and five GNAQ mutant tumors), Illumina class 1 (three GNAQ wild-type and six GNAQ mutant tumors) and

Illumina class 2 (three GNAQ wild-type and six GNAQ-mutant tumors). SAM was performed using the Wilcoxon nonparametric method.

Chromosome 3 Status and Extracellular Matrix Patterns

Chromosome 3 status was available on 42 of the tumors from a previous study using single nucleotide polymorphisms to detect loss of heterozygosity across the entire chromosome.[17] The status of extracellular matrix patterns was available on 13 patients from a previous study.[22] No additional cases in this cohort were available for this analysis.

Statistical Analysis

The patients in this study included a well-characterized cohort of 42 UM patients for whom clinical, pathologic, chromosomal, and transcriptional data have been published.[17,19,20,23] These data included age, gender, tumor diameter and thickness, ciliary body involvement, histologic cell type, depth of scleral invasion, metastasis, patient outcome, transcription profile class 1 or 2, status of chromosome 3, and chromosomal arms 6p, 8p, and 8q, and immunohistochemical staining status for β-catenin, E-cadherin, and cytokeratin-18. These parameters were analyzed for association with GNAQ status (MedCalc ver. 9.4.2.0 statistical software; Med-Calc Software, Mariakerke, Belgium). Categorical variables were analyzed using the Fisher exact test, and continuous variables by the Mann-Whitney test. Metastasis-free survival was analyzed by the Kaplan-Meier method. $P < 0.05$ was considered significant.

RESULTS

Identification of Potential Oncogenes

Genome-wide aCGH data were available on 28 primary UMs,[19] and these data were reanalyzed to search for regional DNA amplifications that could signify the location of oncogenes. Similar techniques previously have been used successfully to identify, among many other examples, *MITF* as an oncogene in cutaneous melanoma.[24] CGHminer analysis identified frequent gains of large regions of 6p and 8q (Fig. 1A), which are known regions of chromosomal gain in UM.[25–29] CGHminer also detected occasional gains across chromosome 20. However, no small, discrete regions of gain were identified on these or other chromosomal arms. Amplification of an oncogene in a subset of tumors has commonly been used as a means of identifying activating mutations in that oncogene in other nonamplified tumor samples. Thus, we searched for discrete regions of DNA gain, defined as one or more contiguous probes with a $\log_2$ratio ≥ 3 SD of the mean for the entire chromosomal arm in at least 15% of tumor samples. Using this technique, a small region of DNA gain was identified on 5q, corresponding to the location of *PIK3R1* (Fig. 1B), the regulatory subunit of phosphatidylinositol 3-kinase, which can activate the RAF/MEK/ERK pathway.[30]

Resequencing of Potential Oncogenes

Along with *PIK3R1*, we selected 12 genes from 6p, 8q, and 20 that are known to play a role in activating the RAF/MEK/ERK pathway, exhibited significant expression in uveal melanocytes and UMs in our previously published microarray expression profiles,[1,19,20] and in most cases, have known mutations in other cancers (Table 1, Fig. 1C). Resequencing of these genes in 19 primary UMs revealed no mutations. We extended our resequencing to include seven more oncogenes: two RAF family members (*ARAF* and *RAF1*), the parallel Ras effector *RASIP1*, two additional genes that are closely linked to activation of RAF (*DIRAS2* and *RAPGEF1*), the RAS homologue activating protein *ARHGAP1*, and the PI3K pathway member *PIP5KL1*. Resequencing of these genes in 19 primary UMs also revealed no mutations. Four additional genes were selected

FIGURE 1. Regions of chromosomal gain identified by CGH. (A) CGH-miner result for 16 class 1 and 12 class 2 tumors. DNA gains (indicated by *orange* and *red vertical bars*) with respect to chromosomal position (*horizontal lines*) on 6p, 8q and, to a lesser extent, 20p and 20q. The p-arms are depicted to the left, and the q-arms to the right of the centromeres (*vertical purple bars*). The percentage of samples showing DNA gain is indicated by the scale at the *bottom*. (B) CGH tracing of chromosome 5, showing two peaks with a mean $\log_2$ratio ≥ 3 SD above the mean for the chromosomal arm. The larger peak at 5q13.1 corresponded to the location of *PIK3R1*. The other smaller peak did not correspond to a coding region. (C) Pathways that affect RAF/MEK/ERK activation. *Arrows*: stimulatory interactions; T-bars: inhibitory interactions. RTK, receptor tyrosine kinase; GPCR, G-protein coupled receptor. Other abbreviations are official gene symbols. Notations of specific genes analyzed in this study: [1]Ras superfamily of small GTPases: *DIRAS2, REM1, GEM, RAB2A, RAB22A, RAB23 (HRAS, KRAS,* and *NRAS* were previously analyzed); [2]*PAK7*; [3]*ARAF, RAF1*, and *RASIP1* (BRAF was previously analyzed); [4]*PTK2* and *PTK6*; [5]*PIK3R1* regulatory subunit; [6]*MAPK13* and *MAPK14*; [7]*GNAQ*; [8]*GRM1*. *Red shapes* indicate genes that were resequenced in the study.

because of a known association with a melanoma phenotype (*EDG5, GNAQ, GRM1,* and *PTPN11*). Mutations were found in *GNAQ,* but not in *EDG5, GRM1,* or *PTPN11* (Fig. 2). In all cases, mutations in *GNAQ* occurred at codon 209 (wild-type sequence: CAA).

GNAQ Mutations in UM

Prompted by the finding of mutations in *GNAQ,* analysis of this gene was expanded to include 67 primary UMs. *GNAQ*

mutations were found in 49% (33/67) of tumors, including 22% (2/9) iris UMs and 54% (31/58) of posterior UMs. Mutant sequences included CCA (22 cases), CTA (13 cases) and CAT (one case). Normal DNA samples from peripheral blood were available from 22 patients with *GNAQ*-mutant primary tumors, and none of these harbored *GNAQ* mutations. Normal uveal melanocytes surrounding the primary tumor were available in two patients with *GNAQ*-mutant tumors (MM86 and MM101), and neither melanocyte samples showed *GNAQ* mutations.

GNAQ Mutations and Tumor Progression

GNAQ mutations exhibited several properties that would be expected for an early or initiating oncogenic event. First, *GNAQ* mutations did not occur preferentially in tumors with clinical, pathologic, or immunohistochemical features indicative of advanced tumor progression (Supplementary Table S2, http://www.iovs.org/cgi/content/full/49/12/5230/DC1). Second, *GNAQ* mutations did not correlate with the degree of chromosomal aneuploidy, which is often used as a surrogate measure of temporal tumor progression ($P = 0.498$; Supplementary Fig. S1, http://www.iovs.org/cgi/content/full/49/12/5230/DC1). Third, there was no correlation between *GNAQ* mutation and class 2 gene expression profile, which is perhaps the most accurate indicator of advanced tumor progression.[1,19,20] For this analysis, 30 tumors that were previously profiled for gene expression were analyzed with respect to *GNAQ* mutation status. Unsupervised analysis using PCA showed no clustering of tumors based on *GNAQ* status (Supplementary Fig. S1). SAM was used to identify genes that were differentially expressed in tumors harboring *GNAQ* mutations. Consistent with the PCA results, SAM revealed no genes that were consistently differentially expressed between tumors with and without *GNAQ* mutations (Supplementary Fig. S1).

DISCUSSION

Activated oncogenic mutations affecting the RAF/MEK/ERK pathway are pervasive in cutaneous melanomas and other forms of cancer, but have rarely been found in UM.[7,8,31] Mutation of *GNAQ* at codon 209, which occurs in about half of UMs, represents the first common oncogene mutation in UM and provides important new insights into UM pathogenesis. GNAQ is a heterotrimeric GTP-binding protein α subunit that couples G-protein coupled receptor signaling to the RAF/MEK/ERF and other intracellular pathways through

FIGURE 2. Representative sequence tracings for *GNAQ* surrounding codon 209 (*shaded*). UM86, normal uveal melanocyte sample; MM31, uveal melanoma with wild-type sequence (CAA); MM37, MM18, and MM88, uveal melanomas with the three mutant sequences, as indicated.

TABLE 1. Summary of Candidate Oncogenes

Gene Symbol	Chromosomal Location	Exons Resequenced	Primary Tumors Analyzed (n)	Tumors with Mutations (n)	RAF/MEK/ERK Pathway	DNA Gain	Mutated in Other Cancers	Pigmentation or Melanoma Phenotype
ARAF	Xp11.4-p11.2	9, 12	19	0	X		X	
ARHGAP1	11p12-q12	11	19	0	X		X	
DIRAS2	9q22.2	1	19	0	X			
EDG5	19p13.2	2	16	0	X			X
GEM	8q13-q21	1–3	19	0	X	X		
GNAQ	9q21	5	67	36	X		X	X
GRM1	6q24	1–8	16	0	X			X
LYN	8q13	12	19	0	X	X	X	
MAPK13	6p21.31	1–11	19	0	X	X	X	
MAPK14	6p21.3-p21.2	1–9	19	0	X	X	X	
PAK7	20p12	10	19	0	X	X	X	
PIK3R1	5q13.1	8	19	0	X	X		
PIP5KL1	9q34.11	3	19	0	X		X	
PSKH2	8q21.2	2	19	0	X	X	X	
PTK2	8q24-qter	19	19	0	X	X	X	
PTK6	20q13.3	1, 7	19	0	X	X	X	
PTPN11	12q24	3–4, 13	16	0	X		X	X
RAB2	8q12.1	1, 2, 4	19	0	X	X		
RAB23	6p11	2–6	19	0	X	X		
RAB22A	20q13.32	1–3	19	0	X	X		
RAF1	3p25	6, 9	19	0	X		X	
RAPGEF1	9q34.3	19	19	0	X		X	
RASIP1	19q13.33	3	19	0	X			
REM1	20q11.21	1–3	19	0	X	X	X	

protein kinase C activated by stimulation of phospholipase C-β.[32] Codon 209 maps to the catalytic domain of GNAQ, which is involved in GTPase activity. Mutation of this codon inactivates the catalytic domain, preventing hydrolysis of GTP and locking GNAQ in its active, GTP-bound state. This mutation leads to melanocyte proliferation in mice,[33] and can cooperate with other oncogenes to transform melanocytes.[16] Constitutive activation of GNAQ mimics growth factor signaling in sensitive cells through activation of the RAF/MEK/ERK pathway and leads to transcriptional activation of cell cycle genes such as *CCND1*. This could explain the frequent overexpression of cyclin D1 in UMs.[12] The finding of *GNAQ* mutations as a common and early mutational event in UM could pave the way for novel targeted therapies aimed at inhibiting the *GNAQ* protein product or other members of the pathway.

In many cancers, mutations in the RAF/MEK/ERK pathway are thought to be early or initiating events in tumorigenesis. For example, BRAF mutations occur very early in cutaneous melanoma, and are even present in benign and premalignant nevi.[34,35] Similarly, the absence of correlation between *GNAQ* mutation and clinical, pathologic, immunohistochemical, and genetic indicators of tumor progression, and the presence of the mutation in tumors at all stages of progression, would support the placement of *GNAQ* mutation as an early event in UM tumorigenesis.

GNAQ mutations were not found in normal DNA from patients bearing *GNAQ*-mutant tumors. This was an important finding, as it indicated that the *GNAQ* mutations were acquired somatically and were not present in the germline. A potential effect of *GNAQ* mutations could be the creation of an expanded pool of morphologically normal but abnormally proliferating melanocytes, as occurred in the mouse model of *GNAQ* mutation.[33] As a result, one may expect to find *GNAQ* mutations in uveal melanocytes of tumor-bearing eyes. However, in two patients with *GNAQ*-mutant tumors from whom we were able to obtain uveal melanocytes, no *GNAQ* mutations were found. *GNAQ* mutations were more

common in UMs located in the posterior uveal tract (ciliary body and choroid) compared to iris UMs, which are located in the anterior uveal tract. Conversely, *BRAF* mutations are found in some iris UMs,[36] but not in posterior UMs. These findings would support the long-held notion that iris UMs and posterior UMs have not only clinical, but also pathogenetic differences.[37]

The finding of *GNAQ* mutations in half of UMs raises the exciting possibility that other important oncogene mutations will be found in the other UMs. The role of GNAQ in activating the RAF/MEK/ERK pathway would suggest that future searches for early oncogenic mutations in UM should focus on genes in this pathway. We screened 23 other potential oncogenes in this pathway. Members of the RAS superfamily of small GTPases are commonly mutated in cutaneous melanoma and other cancers, so we resequenced several members of this family (*DIRAS2*, *REM1*, *GEM*, *RAB2A*, *RAB22A*, and *RAB23*), as well as positive effectors of RAS signaling (*DIRAS2*, *RAPGEF1*, and *RASIP1*), the RAS homolog GTPase activating protein *ARHGAP1*, and the serine/threonine protein kinase *PAK7*, which is an effector of RAS homolog RAC/CDC42 GTPases. *HRAS*, *KRAS*, and *NRAS* previously have been shown to be free of mutations in UM,[6–8] and not analyzed in this study. Similarly, *BRAF* is frequently mutated in cutaneous melanoma and other cancers, but not in UM,[6,7,9,31] so we extended our resequencing to the other RAF family members, *ARAF* and *RAF1*. The PI3K pathway is activated in UMs[38] and can activate MEK/ERK.[30] Thus, we analyzed several members of the PI3K pathway, including *PTPN11*, *PTK2*, *PTK6*, *PIK3R1* (the regulatory subunit of PI3K), and *PIP5KL1*. We also analyzed *GRM1* and *EDG5*, which are G-protein coupled receptors that interact with GNAQ and are associated with melanoma phenotypes.[39–41] Even though our mutational screen revealed no additional oncogenic mutations, this screening was valuable in narrowing the search for oncogenic mutations in future studies. To this list can be added the *GNAQ*-associated genes *GNA12-15*, *GNAS*, and *ENDRB*, which were previously an-

alyzed and found to harbor no mutations in UM.[16] Future studies should continue to focus on screening for mutations in members of this pathway.

References

1. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. *Cancer Res.* 2004;64:7205–7209.
2. Petrausch U, Martus P, Tonnies H, et al. Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. *Eye.* 2008;22(8):997–1007.
3. Tschentscher F, Husing J, Holter T, et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. *Cancer Res.* 2003;63:2578–2584.
4. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. *Biochim Biophys Acta.* 2007;1773:1263–1284.
5. Dahl C, Guldberg P. The genome and epigenome of malignant melanoma. *APMIS.* 2007;115:1161–1176.
6. Rimoldi D, Salvi S, Lienard D, et al. Lack of BRAF mutations in uveal melanoma. *Cancer Res.* 2003;63:5712–5715.
7. Cruz F 3rd, Rubin BP, Wilson D, et al. Absence of BRAF and NRAS mutations in uveal melanoma. *Cancer Res.* 2003;63:5761–5766.
8. Soparker CN, O'Brien JM, Albert DM. Investigation of the role of the ras protooncogene point mutation in human uveal melanomas. *Invest Ophthalmol Vis Sci.* 1993;34:2203–2209.
9. Zuidervaart W, van Nieuwpoort F, Stark M, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. *Br J Cancer.* 2005;92:2032–2038.
10. Calipel A, Mouriaux F, Glotin AL, Malecaze F, Faussat AM, Mascarelli F. Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells. *J Biol Chem.* 2006;281:9238–9250.
11. Coupland SE, Anastassiou G, Stang A, et al. The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. *J Pathol.* 2000;191:120–126.
12. Brantley MA Jr, Harbour JW. Deregulation of the Rb and p53 pathways in uveal melanoma. *Am J Pathol.* 2000;157:1795–1801.
13. Brantley MA Jr, Harbour JW. Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region. *Cancer Res.* 2000;60:4320–4323.
14. Delston RB, Harbour JW. Rb at the interface between cell cycle and apoptotic decisions. *Curr Mol Med.* 2006;6:713–718.
15. Glatz-Krieger K, Pache M, Tapia C, et al. Anatomic site-specific patterns of gene copy number gains in skin, mucosal, and uveal melanomas detected by fluorescence in situ hybridization. *Virchows Arch.* 2006;449(3):328–333.
16. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and intradermal melanocytic proliferations. *Nature.* In press.
17. Onken MD, Worley LA, Person E, Char DH, Bowcock AM, Harbour JW. Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. *Clin Cancer Res.* 2007;13:2923–2927.
18. Sun Y, Tran BN, Worley LA, Delston RB, Harbour JW. Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma. *Invest Ophthalmol Vis Sci.* 2005;46:1561–1564.
19. Worley LA, Onken MD, Person E, et al. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. *Clin Cancer Res.* 2007;13:1466–1471.
20. Onken MD, Ehlers JP, Worley LA, Makita J, Yokota Y, Harbour JW. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. *Cancer Res.* 2006;66:4602–4609.
21. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, eds. *Bioinformatics Methods and Protocols: Methods in Molecular Biology.* Totowa, NJ: Humana Press; 2000:365–386.
22. Onken MD, Lin AY, Worley LA, Folberg R, Harbour JW. Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas. *Am J Ophthalmol.* 2005;140:748–749.
23. Chang SH, Worley LA, Onken MD, Harbour JW. Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. *Melanoma Res.* 2008;18:191–200.
24. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. *Nature.* 2005;436:117–122.
25. Ghazvini S, Char DH, Kroll S, Waldman FM, Pinkel D. Comparative genomic hybridization analysis of archival formalin-fixed paraffin-embedded uveal melanomas. *Cancer Genet Cytogenet.* 1996;90:95–101.
26. Hughes S, Damato BE, Giddings I, Hiscott PS, Humphreys J, Houlston RS. Microarray comparative genomic hybridisation analysis of intraocular uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3. *Br J Cancer.* 2005;93:1191–1196.
27. Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. *Invest Ophthalmol Vis Sci.* 2001;42:313–317.
28. Kilic E, van Gils W, Lodder E, et al. Clinical and cytogenetic analyses in uveal melanoma. *Invest Ophthalmol Vis Sci.* 2006;47:3703–3707.
29. Ehlers JP, Worley L, Onken MD, Harbour JW. Integrative genomic analysis of aneuploidy in uveal melanoma. *Clin Cancer Res.* 2008;14:115–122.
30. Gingery A, Bradley E, Shaw A, Oursler MJ. Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. *J Cell Biochem.* 2003;89:165–179.
31. Weber A, Hengge UR, Urbanik D, et al. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. *Lab Invest.* 2003;83:1771–1776.
32. Ross EM, Wilkie TM. GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. *Annu Rev Biochem.* 2000;69:795–827.
33. Van Raamsdonk CD, Fitch KR, Fuchs H, de Angelis MH, Barsh GS. Effects of G-protein mutations on skin color. *Nat Genet.* 2004;36:961–968.
34. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. *Nature.* 2002;417:949–954.
35. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. *Nat Genet.* 2003;33:19–20.
36. Henriquez F, Janssen C, Kemp EG, Roberts F. The T1799A BRAF mutation is present in iris melanoma. *Invest Ophthalmol Vis Sci.* 2007;48:4897–4900.
37. Henderson E, Margo CE. Iris melanoma. *Arch Pathol Lab Med.* 2008;132:268–272.
38. Ye M, Hu D, Tu L, et al. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. *Invest Ophthalmol Vis Sci.* 2008;49:497–504.
39. Pollock PM, Cohen-Solal K, Sood R, et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. *Nat Genet.* 2003;34:108–112.
40. Kono M, Belyantseva IA, Skoura A, et al. Deafness and stria vascularis defects in S1P2 receptor-null mice. *J Biol Chem.* 2007;282:10690–10696.
41. Kim D-S, Hwang E-S, Lee J-E, Kim S-Y, Kwon S-B, Park K-C. Sphingosine-1-phosphate decreases melanin synthesis via sustained ERK activation and subsequent MITF degradation. *J Cell Sci.* 2003;116:1699–1706.